Gridai Technologies Corp. (GRDX) closed at $5.42 on November 12, 2026, down 2.3% from the previous close, on volume of 58,791 shares (30-day average 106,634).
Data as of November 12, 2026.
GRDX Targets 300 MW in 2027 After Deal for Pronghorn’s ~100 MMcf/day Wyoming Gas Platform
Market Chameleon (Fri, 13-Nov 5:52 AM ET)
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Gridai Technologies Corp. trades on the NASDAQ stock market under the symbol GRDX.
As of November 13, 2026, GRDX stock price declined to $3.87 with 324,013 million shares trading.
GRDX has a beta of 2.48, meaning it tends to be more sensitive to market movements. GRDX has a correlation of 0.05 to the broad based SPY ETF.
GRDX has a market cap of $34.40 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that GRDX belongs to (by Net Assets): VXF, DFSU.
GRDX support price is $4.98 and resistance is $5.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRDX shares will trade within this expected range on the day.
